» Authors » Michael Forster

Michael Forster

Explore the profile of Michael Forster including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 128
Citations 2340
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Rudalska R, Harbig J, Forster M, Woelffing P, Esposito A, Kudolo M, et al.
Nat Cancer . 2025 Jan; 6(2):259-277. PMID: 39820127
Colorectal cancer (CRC) constitutes the second leading cause of cancer-related death worldwide and advanced CRCs are resistant to targeted therapies, chemotherapies and immunotherapies. p38α (Mapk14) has been suggested as a...
2.
Oelschlager L, Kunstner A, Frey F, Leitner T, Leypoldt L, Reimer N, et al.
Int J Mol Sci . 2025 Jan; 25(24. PMID: 39769182
The complex and heterogeneous genomic landscape of multiple myeloma (MM) and many of its clinical and prognostic implications remains to be understood. In other cancers, such as breast cancer, using...
3.
Malentacchi F, Mancini I, Villari D, Forster M, Marzocco A, Galli I, et al.
Curr Issues Mol Biol . 2024 Dec; 46(12):13881-13892. PMID: 39727957
Circulating tumor cells and cell-free nucleic acids are novel diagnostic, prognostic and predictive tools for non-invasive and cost-effective cancer detection in liquid biopsy. Carbonic anhydrase IX (CAIX) has been proposed...
4.
Wang G, Seidler N, Rohm S, Pan Y, Liang X, Haarer L, et al.
Angew Chem Int Ed Engl . 2024 Dec; 64(8):e202419736. PMID: 39716901
Protein kinases are important drug targets, yet specific inhibitors have been developed for only a fraction of the more than 500 human kinases. A major challenge in designing inhibitors for...
5.
Burtin F, Elias L, Hinz S, Forster M, Hildebrandt G, Frerker B, et al.
J Cancer Res Clin Oncol . 2024 Sep; 150(9):428. PMID: 39307893
Background: Liquid biopsy is a minimally invasive procedure investigating tumor mutations. Methods: In our retrospective study, we investigated whether molecular therapy monitoring of patients receiving neoadjuvant radio(chemo)therapy on a daily...
6.
Grimsrud M, Forster M, Goeppert B, Hemmrich-Stanisak G, Sax I, Grzyb K, et al.
Hepatol Commun . 2024 Jul; 8(7). PMID: 38967597
Background: People with primary sclerosing cholangitis (PSC) have a 20% lifetime risk of biliary tract cancer (BTC). Using whole-exome sequencing, we characterized genomic alterations in tissue samples from BTC with...
7.
Baumann A, Ruckert C, Meier C, Hutschenreiter T, Remy R, Schnur B, et al.
Eur J Hum Genet . 2024 Jun; 32(8):987-997. PMID: 38907004
Considering polygenic risk scores (PRSs) in individual risk prediction is increasingly implemented in genetic testing for hereditary breast cancer (BC) based on next-generation sequencing (NGS). To calculate individual BC risks,...
8.
Magadeeva S, Qian X, Korff N, Florkemeier I, Hedemann N, Rogmans C, et al.
Int J Mol Sci . 2023 Dec; 24(24). PMID: 38139296
Ovarian cancer (OC) cells with homologous recombination deficiency (HRD) accumulate genomic scars (LST, TAI, and LOH) over a value of 42 in sum. PARP inhibitors can treat OC with HRD....
9.
Bolke S, Fruh A, Trilling F, Forster M, Scherf U, Chasse T, et al.
Molecules . 2023 Sep; 28(18). PMID: 37764211
Ladder polymers with poly(diketopyrrolopyrrole) (DPP) moieties have recently attracted enormous interest for a large variety of opto-electronic applications. Since the rigidity of the backbone increases with ladderization, a strong influence...
10.
Mansour A, Warren R, Lungwitz D, Forster M, Scherf U, Opitz A, et al.
ACS Appl Mater Interfaces . 2023 Sep; 15(39):46148-46156. PMID: 37730205
Strong molecular dopants for organic semiconductors that are stable against diffusion are in demand, enhancing the performance of organic optoelectronic devices. The conventionally used p-dopants based on 7,7,8,8-tetracyanoquinodimethane (TCNQ) and...